There has been plenty of chatter about whether GLP-1 drugs might be longevity drugs in disguise. A new study in Nature adds the most direct preclinical evidence yet: semaglutide extended lifespan in already-aged female mice.
The mice were 20 months old when treatment began, well into late life by laboratory standards. Semaglutide (a popular GLP-1 agonist) reduced the mice’s food intake and body weight, just like it does in humans. But the treated mice also lived longer, moved more, coordinated their movements better, maintained better glucose control, and performed better on tests of spatial memory.1
The survival result is the big headline here (with a few caveats we’ll get into later). Median lifespan was 742 days in the untreated mice and 834 days in the semaglutide mice: an increase of 92 days, or about 12%. This was not simply a case of preventing a single disease, either. Several parts of their health held up better with age, suggesting that semaglutide slowed aging more broadly.
That makes the timing of the intervention especially important: the treatment began after aging was already well underway. By that point, the question is no longer whether the animals can be kept young, but whether an aging trajectory can still be altered later in life. In this experiment, it could.
The Biology Behind the Result
When most people think about GLP-1s, their brain goes straight to weight loss. That was part of the story here, but not all of it.
In this study, led by first-author Dr. Yufan Feng, it’s true that the treated mice lost weight, but semaglutide also shifted several systems that tend to deteriorate with age: inflammation and cellular senescence went down, mitochondrial function improved, and markers of DNA damage and oxidative stress were reduced. The mice also had more ATP and NAD⁺ – molecules involved in cellular energy and maintenance – and better protein quality control, which helps cells deal with damaged or misfolded proteins.
The brain findings were especially interesting. Semaglutide increased neural stem-cell activity and increased the formation of new neurons in the hippocampus, a brain region involved in learning and memory. That gives some biological context to the treated mice’s improved performance on spatial-memory tests, although it can’t prove that the new neurons caused the better memory.
The researchers also compared semaglutide with calorie restriction, one of the most reliable ways to extend lifespan in laboratory animals. The calorie-restricted mice received 24% fewer calories. The semaglutide mice ate less because the drug suppressed their appetite.
Both groups lost weight and fat and preserved some measures of movement, coordination, muscle function, endurance, and glucose control compared with untreated animals. But the treatments were not identical. The calorie-restricted mice ate their food quickly and then spent most of the day fasting, whereas the semaglutide-treated mice ate less gradually.
The semaglutide mice also showed better results on measures like spatial memory and glucose control. That suggests the drug may be doing more than simply making the mice eat less. It seems to reproduce part of the calorie-restriction response while also affecting other systems in the brain and body.
The researchers saw changes in several of the cell systems linked to aging, including those involved in energy use, repair, and growth. The overall pattern looked similar to calorie restriction, but it was not an exact copy.
We spoke with Dr. Danica Chen, Professor of Metabolic Biology & Nutrition at University of California at Berkeley and principal investigator of this study, who said this particular result was a surprise for her. “We thought the drug would have the same effect as calorie restriction, and we were surprised that for several measures (spatial memory, exploratory drive, glucose metabolism), the drug worked better than calorie restriction. More surprisingly, improved above the baseline level. So not just slowing aging-related decline, but reversing it.”
Why GLP-1s are in the Longevity Conversation
This Nature paper arrives mid-conversation. GLP-1 receptor agonists have long been discussed as possible longevity therapies largely because their effects reach well beyond blood sugar and body weight.
A large Veterans Affairs analysis of more than 200,000 people found that GLP-1 receptor agonist use was associated with lower risks of cardiometabolic disease, neurocognitive disorders including Alzheimer’s disease and dementia, coagulation disorders, infectious illness, and several other outcomes.2 These findings are observational, so they cannot prove that GLP-1 drugs caused the reductions. They do, however, support the idea that the drugs may influence several of the diseases that determine how long people live and how healthy they remain.
A large, randomized study offers stronger evidence for that possibility. In the SELECT trial, more than 17,000 adults with overweight or obesity, established cardiovascular disease, and no diabetes received weekly semaglutide or placebo. After roughly three years, semaglutide reduced major cardiovascular events by 20% and was linked to a lower risk of death from any cause.3
The trial was not designed to test whether semaglutide slows aging. But it demonstrates one obvious way the drug could help people live longer: by preventing heart attacks and strokes, which cause a substantial number of deaths in people with cardiovascular disease and obesity.
By that definition, a lot of modern medicine starts to look like longevity medicine. Statins, blood-pressure drugs, vaccines, cancer screening – anything that prevents an early death could qualify. It begs the question of what, then, isn’t a longevity drug? But that’s a conversation for another day.
Growing evidence suggests that GLP-1 receptor agonists specifically alter the biology of aging. A recent study of aged male mice showed that GLP-1 receptor agonists specifically improved multiple age-related molecular changes and declines in physical function. The effects were strongest when treatment began later in life and the molecular changes also showed striking similarities to those produced by mTOR inhibition, one of the better-established anti-aging interventions in animals.4
That study suggested that GLP-1 signaling influences the biology of aging, but it did not show that the mice lived longer. The new Nature paper takes the next step. Semaglutide not only shifted aging-related pathways and improved function, but it also extended survival when treatment began late in life.
That combination is what makes the result important. GLP-1 drugs were already plausible longevity therapies because they can reduce the diseases that kill people. They are now also being evaluated against aging itself and, in these mice, passed a major test.
The Longevity Question
They are now serious candidates in the longevity conversation. The question is no longer whether GLP-1 biology has anything to do with aging (it clearly does) but whether these effects can be translated into longer, healthier lives in humans.
The strongest evidence for a direct lifespan effect still comes from mice, including the recent Nature study. But the study also leaves important questions open. It used only female mice, so we do not yet know whether the same lifespan effect occurs in males. (Note that this was a deliberate choice: the researchers wanted to avoid injuries and other complications associated with male aggression in group-housed animals). The animals were a single mouse strain, treated with a daily regimen under tightly controlled conditions. Results could differ with other types of animals, diets, dosing schedules, or existing diseases.
Early criticism of the paper has focused on the untreated mice, which had a median lifespan of 742 days – shorter than some published estimates for similar mice. If the control mice did not live a typical lifespan, how confidently can we judge the drug’s benefit? That is a fair question. But there is no single agreed-upon “normal” lifespan for laboratory mice. Lifespan can vary with the facility, colony, strain, diet, housing, and study design. The 742-day median is within the published range, but comparisons with other studies cannot settle the issue. The clearest comparison is still the one made within this experiment: the semaglutide-treated mice lived longer than the control mice raised under the same conditions.
The human evidence is encouraging but indirect. Studies can show that people taking GLP-1 drugs have fewer health problems, but they cannot completely rule out other explanations. GLP-1 users may differ from non-users in healthcare access, medication adherence, baseline health, weight, or disease severity.
There are also practical concerns. GLP-1 drugs can cause substantial gastrointestinal side effects, and women appear to lose somewhat more weight than men.5 In older adults, weight loss is not automatically beneficial if too much of it comes from lean tissue so maintaining muscle, strength, and physical function will be essential if these drugs are ever used specifically to extend healthspan. A treatment that keeps an animal alive longer but frail would be a disappointing longevity intervention.
Dr. Chen had already thought about this possibility. “We were worried that aged non-obese mice might not tolerate the drug and weight loss well and become very weak,” she said. “We also knew calorie restriction initiated at old age might not result in lifespan extension. We were surprised the mice were stronger and lived longer.”
Despite the fanfare this study has generated even in the last 48 hours, we should be careful not to rush into stamping semaglutide as a Bonafide anti-aging drug. The next step is to test whether these findings hold across different animals, treatment schedules, and eventually humans, while measuring more than weight or disease risk. Frailty, muscle function, cognition, disability, quality of life, and survival will all matter.
Of course there are real limitations to take into account, including the short lifespan of the control mice and the use of only female animals. But this study has produced a result that is difficult to dismiss: in old mice, semaglutide improved function and extended life. This development cannot settle the human longevity question, but it makes the question considerably harder to ignore.
References
- Feng, Y. et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature 1–8 (2026) doi:10.1038/s41586-026-10940-7.
- Xie, Y., Choi, T. & Al-Aly, Z. Mapping the effectiveness and risks of GLP-1 receptor agonists. Nat. Med. 31, 951–962 (2025) doi:10.1038/s41591-024-03412-w.
- Lincoff, A. M. et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N. Engl. J. Med. 389, 2221–2232 (2023) doi:10.1056/NEJMoa2307563.
- Huang, J. et al. Body-wide multi-omic counteraction of aging with GLP-1R agonism. Cell Metab. 37, 2362-2380.e8 (2025) doi:10.1016/j.cmet.2025.10.014.
- Yang, Y. et al. Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis. J. Diabetes 17, e70063 (2025) doi:10.1111/1753-0407.70063.
Lifespan Magazine is proud to support medical research and the Lifespan Foundation
Last Updated: Sep 8, 2026 · 8 minute
